BCL2 and cholangiocarcinoma: Essentially, our results indicate that CBD influences the signaling pathways of LC3II and p62, while simultaneously reducing the expression of certain proteins such as p-PI3K, p-AKT, p-mTOR, and Bcl-2 in CCA cells, suggesting that CBD has potential therapeutic application in various cancer types, including CCA.